Matinas Bio Pharma
Biotechnology, 1545 Rte 206th, Bedminster, New Jersey, 07921, United States, 11-50 Employees
Phone Number: 90********
Who is MATINAS BIOPHARMA
Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) pl...
Read More
-
Headquarters: 1545 Rte 206th, Bedminster, New Jersey, 07921, United States
-
Date Founded: 2011
-
Employees: 11-50
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
-
CEO:
Jerry Jabbour
Email
Phone
Industry: Biotechnology
SIC Code: 2833
|
NAICS Code: 541715 |
Show More
Does something look wrong? Fix it. | View contact records from MATINAS BIOPHARMA
Matinas BioPharma Org Chart and Mapping
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Matinas BioPharma
Answer: Matinas BioPharma's headquarters are located at 1545 Rte 206th, Bedminster, New Jersey, 07921, United States
Answer: Matinas BioPharma's phone number is 90********
Answer: Matinas BioPharma's official website is https://matinasbiopharma.com
Answer: Matinas BioPharma's revenue is $10 Million to $25 Million
Answer: Matinas BioPharma's SIC: 2833
Answer: Matinas BioPharma's NAICS: 541715
Answer: Matinas BioPharma has 11-50 employees
Answer: Matinas BioPharma is in Biotechnology
Answer: Matinas BioPharma contact info: Phone number: 90******** Website: https://matinasbiopharma.com
Answer: Matinas BioPharma (NYSE AMER: MTNB) is a biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology. The Company is developing its own internal portfolio of products as well as partnering with leading pharmaceutical companies to develop novel formulations that capitalize on the unique characteristics of the LNC platform. Preclinical and clinical data have demonstrated that this novel technology can provide solutions to many of the challenges in achieving safe and effective intracellular delivery, for both small molecules and larger, more complex molecules, such as mRNA, DNA plasmids, antisense oligonucleotides, and vaccines. The combination of a unique mechanism of action and flexibility with formulation and route of administration (including oral), positions Matinas LNC technology to potentially become the preferred next-generation intracellular drug delivery vehicle with distinct advantages over both lipid nanoparticles and viral vectors.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month